Big pharma, battling COVID-19, looks to 'buy time' on another health crisis: superbugs

Leading drug companies announced Thursday a partnership that has raised nearly $1 billion, with the aim of having two to four new antibiotics available by 2030.

"COVID-19 came along while we were discussing this, and I think for us really crystallized the impact of public health crises and the incredibly important role this industry has in addressing those," Lilly CEO David Ricks said during a virtual event announcing the launch of the Antimicrobial Resistance Action Fund.